PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Landegren Gene Technology AB	09/17/2005

RECEIVING PARTY DATA

Name:	Guldskalen D 412 AB
Street Address:	Dag Hammarskjolds vag 54A
City:	Uppsala
State/Country:	SWEDEN
Postal Code:	751 83

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	10495895

CH $40.00 10495895

CORRESPONDENCE DATA

Fax Number: (513)421-0991
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 5133694224
Email: hkozlowski@porterwright.com
Correspondent Name: Holly D. Kozlowski
Address Line 1: 41 South High Street
Address Line 2: Porter Wright Morris & Arthur
Address Line 4: Columbus, OHIO 43215

ATTORNEY DOCKET NUMBER:	3995937-174117
NAME OF SUBMITTER:	Holly D. Kozlowski

Total Attachments: 6
source=LandegrenGeneTechnologyAssignment#page1.tif
source=LandegrenGeneTechnologyAssignment#page2.tif
source=LandegrenGeneTechnologyAssignment#page3.tif
source=LandegrenGeneTechnologyAssignment#page4.tif

source=LandegrenGeneTechnologyAssignment#page5.tif
source=LandegrenGeneTechnologyAssignment#page6.tif

AGREEMENT

REGARDING TRANSFER OF INTELLECTUAL AND PROPRIETARY RIGHTS TO PATENT(S)

1. **PARTIES**

Guldskålen D 412 AB, 556663-6998, under name-change to Olink AB, hereinafter referred to as "the Company", and

Landegren Gene Technology AB, 556515-6725, hereinafter referred to as "the Transferor".

2. **BACKGROUND**

2.1 The Company has been set up to establish the Proximity and Padlock detection method on several platforms as a standard for demanding protein analysis within life science research, routine applications and diagnostics.

2.2 The Transferor possesses certain rights to patent(s)/patent application(s) as set out in exhibit 2.2, hereinafter referred to as the Patent(s).

2.2 The Transferor is one of the founders of the Company and is willing to transfer to the Company the line of business, comprised by the Patents, necessary for the Company to commence its business.

3. **ASSIGNMENT**

3.1 The Transferor hereby irrevocably grants and assigns to the Company all rights in and to the Patent(s) and to all results, discoveries or inventions that falls under the Patent(s), hereinafter referred to as "the Inventions", including the right to sell, license or otherwise transfer the Patent(s) or the Inventions.

3.2 The Transferor shall assist the Company in obtaining/maintaining patent rights and/or other intellectual property rights and thereby sign such documents and take such other measures to create, maintain, transfer or otherwise dispose of the Patent(s) or the Inventions, which is requested by the Company from time to time. This obligation shall survive the expiry/termination of this agreement. The costs and expenses connected with the procedures for obtaining said rights shall be borne by the Company.

4. **TRANSFERORS WARRANTIES**

4.1 The Transferor represents and warrants that its right to the Patent(s) and the Inventions is complete and unrestricted, save as set out in exhibit 4.1.

5. **CONDITIONAL PROVISIONS, OPTION, PLEDGE**

The validity of this Agreement is conditional upon and subject to the occurrence of the following:

The Company raises financing of MSEK 5 in aggregate prior to February 28, 2005.

5.1 If the condition under section 5.1 above is not met by February 28, 2005, all performances shall be returned and this agreement shall be null and void.

5.2 The Company hereby grants to the Transferor an exclusive and irrevocable option, in case the Company becomes insolvent, makes a general assignment for the benefit of creditors, becomes subject to any proceeding under any bankruptcy or insolvency law or has wound up or liquidated, voluntarily or otherwise, prior to December 31, 2005, to acquire the Patents and Inventions transferred hereunder at the same price as the Company pays under this Agreement. For the avoidance of doubt, the Transferor shall have no rights in this respect after December 31, 2005.

5.3 As security for its obligations under this Agreement the Company hereby pledges the Patents in favour of the Transferor and undertake to take all necessary actions, including execution of relevant and necessary documents, in order to register the pledge and to assume all costs connected therewith.

6. CONFIDENTIALITY

6.1 The Transferor hereby undertakes to keep all information regarding the Patent(s) and the Inventions in strict confidence, and not disclose such information to any third party, unless after having obtained written approval from the Company. The obligations hereunder shall survive the expiry/termination of this agreement.

7. TERM AND TERMINATION

7.1 This agreement enters into force on the date of its execution and will remain in force as long as the Company upholds its rights to the Inventions.

8. CONSIDERATION

8.1 In consideration of the assignment made and obligation and undertakings by the Transferor under this agreement, the Company shall pay the Transferor a down payment of SEK 88.475 to be paid within 90 days after execution of this Agreement.

9. DISPUTES

9.1 This agreement shall be governed by and construed under the substantive laws of Sweden.

9.2 Any dispute, controversy or claim arising out of or in connection with this agreement, or regarding any legal relations arising out of or in connection therewith, shall be finally settled by arbitration in accordance with the rules of the Arbitration Institute of the Stockholm Chamber of Commerce. The Arbitration Tribunal shall be composed of one arbitrator appointed by the Arbitration Institute.

This agreement has been executed in two (2) identical copies, of which each of the parties has taken one.

Place: Uppsala Place: Uppsala

Date: 17 sept 2004 Date: September 17, 2004

Guldskålen D 412 AB under name-change to Olink AB

Björn Ekström enligt fullmakt

The Transferor

Ulf Landegren

IP transfer from Landegren Gene technology AB, Ulf Landegren to Olink AB
Date: 16 September, 2004
By: Björn Ekström

17 Brann P05660	WO9522623 Patents US5871921 DE FR GB IT NL CH Application JP	Padlock 1	The invention relates to a method of detecting a target nucleic acid sequence in a sample by contacting the sample with a detectable probe to hybridize the probe to the target sequence, and detecting the hybridized probe. The method comprises the steps of: a) providing a detectable probe comprising two free nucleic acid end parts which are capable of hybridizing to two at least substantially neighbouring regions of the target sequence, b) hybridizing the probe ends to the target sequence under hybridizing conditions, c) convalently connecting the ends of the hybridized probe with each other to form a cyclized structure interlocking with the target molecule, d) subjecting the target sequence to non-hybridizing conditions and/or exonuclease activity to remove any non-cyclized probe from the target sequence, thereby retaining only the cyclized probe bound to the target molecule, e) optionally repeating steps b) to d) one or more times, and f) detecting the presence, and if desired, location of remaining labelled probe as indictative of the presence of the target nucleic acid sequence. The invention also relates to a detecting reagent or probe as well as a kit for use in the method.  LANDEGREN ULF (SE); KWIATKOWSKI MAREK (SE)
8 Brann P05641	WO9741254 Patents CH DE FR GB Applications	Padlock 2	The present invention relates to improved methods for probing of specific nucleic acids using circularizable probes designed such that they report the presence of a target sequence by allowing a detectable moiety to remain bound if and only if the probe has been cyclized in a target-dependent linking reaction. The invention may be used for distinction between sequence specific variations of nucleic acids. LANDEGREN ULF (SE)

	US JP CA		
9 Brann P03708	WO9709069 Patents DE FR GB IT NL SE Applications US	Padlock 3	The present invention relates to methods and compositions for targeting nucleic acid sequences, more specifically double stranded nucleic acid sequences. The compositions comprise oligonucleotides in the form of padlock probes. The padlock probes have two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence. Furthermore, the invention relates to use of said compositions as medicaments for treating genetic disorders. LANDEGREN ULF (SE)
5 Brann P06020	WO9949079 Patents US6558928 Appliactions US divisional 2003 CA EP JP	Padlock 4	Rolling circle replication of a padlock primer is inhibited when it is hybridised to a target nucleic acid that is long or circular. The invention provides methods of addressing this problem including cutting the target nucleic acid near or preferably at the site which hybridises with the padlock probe, whereby a 3'-end of the cut target nucleic acid acts as a primer for rolling circle replication of the padlock probe. Also included is a method for assaying for a polyepitopic target by the use of two affinity probes each carrying an oligonucleotide tag and of padlock probe for rolling circle replication in association with the two affinity probes.  LANDEGREN ULF (SE)
2 Brann P06015	WO03012119 Patents Applications US	Padlock 6	A nucleic acid amplification method, and probes for use within the method are described. CLAIMS1. A method of analyzing circularized nucleic acids, by providing an amplification product, amplifying the said circularized DNA, which product comprises a concatemer of a sequence to be analyzed ; the method further comprising the steps of: a) directly detecting the said amplification product in a homogenous hybridization reaction using singly-or ratio-labeled probes, wherein the said homogenous hybridization detection is based on an enrichment of the detection

	CA EP JP		probes in the said amplification product, and/or by using a modified molecular beacon design; or - b) carrying out a further signal generating reaction, comprising at least one of the following : I) providing a degradable signaling probe that is selectively degraded when it has hybridized to the said amplification product, wherein degraded probes dissociate from the said amplification product allowing further signaling probes to hybridize with the product, wherein hybridization and degradation of the probes effects a change in signal emitted by the probe. GULLBERG MATS (SE); LANDEGREN ULF (SE); NILSSON MATS (SE)
1 Brann P06017	WO03044229 Patents Applications US EP GB	Padlock 7	This invention relates to methods, reagents and kits for enriching nucleic acid sequences. More particularly, the present invention relates to methods, reagents and kits for sample preparation including sample modification, sample enrichment and amplification CLAIMS 1. A method of enriching a preselected nucleic acid segment from a mixture of nucleic acid sequences, the preselected nucleic acid sequence encompassing a specific variant at a given position, the method comprising the steps of: (a) providing a nucleic acid mixture of sequences which includes the preselected nucleic acid segment to be enriched; (b) cleaving the nucleic acid sequences in the mixture to provide a nucleic acid fragment comprising the preselected nucleic acid segment; (c) providing a template oligonucleotide, one end of which hybridises to a sequence of the segment at or close to the variant position, and the other end of which hybridises to the end of a protecting sequence; (d) hybridising the template to the nucleic acid segment and to the protecting sequence such that the variant position and the end of the protecting sequence are brought into proximity of each other; (e) joining the end of the protecting sequence to the nucleic acid segment to form a ligated product, which ligated product is protected from degradation; and (f) enriching for the ligated sequence. GULLBERG MATS (SE); LANDEGREN ULF (SE)
10 Brann P03659	WO9700446 Patents DE69614539D AU702125 SE0504798 CH FR GB IT Applications US CA JP	Prox 1	The present invention relates to an immunological test kit and immunoassay using a first immobilized antibody having affinity for a specific antigen. The invention is characterized by a second and third antibody being specific for different determinants of the antigen and modified with cross-linkable oligonucleotides. For detection, the oligonucleotides are amplified, whereby only such oligonucleotides will be amplified which have been cross-linked to each other. In this way unspecific background is avoided and detection is possible down to single molecules.

			 LANDEGREN ULF (SE)
4 Brann P05050	WO0161037 Patents SE Applications US AU CA EP JP	Prox 2	The present invention relates to sensitive, rapid and convenient assays for detection and/or quantification of one or several analyte(s) in solution using so called proximity probes. The proximity probes comprise a binding moiety and a nucleic acid. The nucleic acid from one proximity probe is only capable of interaction with the nucleic acid from the other proximity probe when these are in close proximity, i.e. have bound to the analytes for which they are specific. The present invention relates to methods and kits for proximity probing and are performed in solution without the need of a solid phase. FREDRIKSSON SIMON (SE); LANDEGREN ULF (SE)